5th Floor, Rajapushpa Summit
Nanakramguda Rd, Financial District, Gachibowli
Hyderabad, Telangana - 500008
The swine healthcare market is segmented by Products (Diagnostic Tests and Therapeutics), Diseases, and Geography
2018 - 2026
Fastest Growing Market:
The global swine health market is expected to register a healthy CAGR during the forecast period, owing to the increasing incidence of swine diseases. The Food and Agriculture Organization of the United Nations (FAO) 2019 report stated that a total of 62 provinces/cities reported outbreaks, about 3,700,000 pigs have died from the African swine fever (ASF). Moreover, rising investments in R&D activities in the development of novel therapeutics, a growing number of governments initiatives for the prevention of zoonotic diseases, increasing demand for livestock products are expected to propel the global swine health market.
Swine health is associated with various diseases caused due to pigs and the development of therapeutics to prevent the related ailments and disorders. Pig breeding can lead to many diseases such as reproductive disease and congenital malformations. Pig production is an important component of global food security, agricultural economies, and local and international trade. Infectious diseases impact pig health and the stability and productivity of the global swine industry.
|Exudative dermatitis (greasy pig disease)|
Report scope can be customized per your requirements. Click here.
Vaccines are comprised of viruses, bacteria or other disease-causing organisms that have been killed or altered. Hence, they cannot cause any disease and boost up immunity. New advanced vaccines have been manufactured, which contains genetically engineered components derived from those disease agents. They are given to pigs, usually by injection, to stimulate an immune response which will protect the pigs against later natural infection with the organism from which the vaccine was derived. Most of the vaccines stimulate both a humoral response and a cell-mediated response. Vaccines can be live, containing living organisms which will multiply in the pig, or inactivated, containing only killed organisms which will not multiply in the pig. As there is a need for novel vaccines against all the disease-causing pathogens, there is a rapid increase in the R&D expenditure, which drives the vaccine segment to expand its reach to a broad spectrum of diseases. For Instance, in May 2017, Boehringer Ingelheim (BI) received approval for its FLEXMycoPRRS, the first and only combination PRRS-Mycoplasma hyopneumoniae (Mhp) vaccine was approved in the U.S. The newest addition to the existing FLEX line of combination swine vaccines helps swine producers better manage respiratory diseases as part of a customized program of whole herd health.
To understand key trends, Download Sample Report
North America is expected to dominate the market due to the rising incidence of swine infections, such as Swine Enteric Coronavirus Diseases (SECD), porcine epidemic diarrhoea (PEDv), porcine delta coronavirus (PDCoV), which has caused significant morbidity and mortality, particularly in young piglets. The virus is endemic in swine populations in North America. In the United States, the Swine Health Protection Act (SHPA) regulates the meat products fed to swine. Compliance with this act ensures that all food waste fed to swine is properly treated to kill disease organisms. Raw meat may transmit numerous infectious or communicable diseases to swine. Over the forecast period, with the rise in the incidence of swine, the US is expected to be a major revenue-generating region for the swine health market. According to the National Center for Biotechnology Information report published in 2018, about 6 million feral swine roam in the US and are believed to be found in at least 35 states leading to the Classical swine fever (CSF) among the people in the United States
To understand geography trends, Download Sample Report.
The market players in the swine health market are involving in various growth strategies such as collaborations, partnerships, agreements, mergers, and acquisitions in order to enhance the market presence. For instance, in 2018 Elanco Animal Health, introduced Prevacent PRRS a modified-live respiratory vaccine for reduction of the porcine reproductive and respiratory syndrome (PRRS), respiratory form, in piglets two weeks or older. In May 2019, MSD Animal Health has launched its Porcilis Ery+Parvo+Lepto combination vaccine for pigs.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Swine Diseases
4.2.2 Increasing Demand for Livestock Products
4.2.3 Increasing Investments in R&D Activities to Develop Novel Therapeutics
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 High cost associated with Swine Health Especially in the Developing Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By products
5.1.1 Diagnostic Tests
184.108.40.206 Enzyme Linked Immuno-Sorbent Assay (ELISA)
220.127.116.11 Rapid Immuno Migration (RIM)
18.104.22.168 Agar Gel Immuno-Diffusion (AGID)
22.214.171.124 Polymerase Chain Reaction (PCR)
126.96.36.199 Diagnostic Imaging
188.8.131.52 Other Diagnostics
184.108.40.206 Feed additives
220.127.116.11 Other Therapeutics
5.2 By Diseases
5.2.1 Exudative dermatitis (greasy pig disease)
5.2.3 Respiratory diseases
5.2.4 Swine dysentery
5.2.5 Porcine parvovirus
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
5.3.3 Asia Pacific
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 C. Boehringer Ingelheim GmBH
6.1.2 Ceva Animal Health Inc.
6.1.5 Merck & Co Inc.
6.1.6 Vetoquinol SA
6.1.8 Zoetis Animal Healthcare
6.1.9 IDEXX Laboratories Inc.
6.1.10 Phibro Animal Health
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments